Yes, This Statement is Absolutely True and Critical for Patient Safety
Patients who are hepatitis B surface antigen positive (HBsAg+) and taking TDF/FTC or TAF/FTC as PrEP must never stop these medications abruptly without consulting their clinician, as this can trigger severe and potentially life-threatening hepatitis B flares (hepatic reactivation). 1, 2
Why This is a Medical Emergency Risk
The FDA drug labels for both tenofovir disoproxil fumarate and emtricitabine explicitly warn that severe acute exacerbations of hepatitis B have been reported in patients who discontinue these medications 1, 2. These are not mild flares—they can be life-threatening. The mechanism is straightforward: TDF/FTC and TAF/FTC have potent anti-HBV activity, and when you suddenly remove this viral suppression, HBV can rebound aggressively, causing acute hepatic decompensation.
The Evidence Base
FDA mandates that all patients be tested for HBV before starting tenofovir-containing regimens, and those with chronic HBV require close medical follow-up for several months after stopping to monitor for hepatitis exacerbations 1
The 2025 EASL guidelines emphasize that antiviral therapy with nucleos(t)ide analogues (NAs) should only be discontinued after consultation with a physician experienced in hepatitis B treatment, with guaranteed close monitoring 3
Recent systematic review data (2026) confirms that in people with active HBV infection, HBV DNA increases or hepatitis flares commonly occurred after tenofovir cessation 4
What Happens When You Stop Without Supervision
For Active HBV Infection (HBsAg+):
- HBV DNA levels surge as viral replication is no longer suppressed
- ALT flares can be severe—one recent study reported 6 patients with severe ALT flares after TDF discontinuation, with 2 requiring hospitalization and 1 death 5
- Hepatic decompensation can occur rapidly, particularly in those with underlying cirrhosis or advanced fibrosis
The Clinical Reality:
The 2020 IAS-USA guidelines specifically state that patients with HIV and HBV co-infection switching therapy should continue tenofovir unless contraindicated, and switching to regimens excluding tenofovir will not maintain HBV suppression 6. This principle applies equally to PrEP patients with chronic HBV.
The Proper Approach to Discontinuation
If a patient needs or wants to stop PrEP and has chronic HBV:
Mandatory specialist consultation before any medication changes 3
Assessment of multiple factors:
- HBsAg levels and HBeAg status
- Duration of HBV DNA suppression
- Stage of liver fibrosis
- Presence of cirrhosis (absolute contraindication to abrupt cessation)
- Patient understanding and ability to comply with monitoring 3
Alternative HBV therapy must be arranged if tenofovir is discontinued—you cannot simply stop without replacement therapy for active HBV 6
Intensive post-cessation monitoring is required for several months, including:
- Regular HBV DNA levels
- ALT monitoring
- HBsAg levels
- Clinical assessment for signs of hepatic decompensation 1
Common Pitfalls to Avoid
- Never assume the patient knows they have HBV—many are unaware of their status
- Don't rely on patient self-monitoring—hepatitis flares can progress rapidly before symptoms appear
- Don't stop tenofovir just because HIV PrEP is no longer needed—the HBV indication may still require treatment
- Don't switch to non-tenofovir regimens without HBV specialist input in HBsAg+ patients 7
Bottom Line
The statement in question is medically accurate and represents a critical safety warning. The risk of hepatitis B reactivation after stopping tenofovir-containing regimens in HBsAg+ patients is well-documented, potentially severe, and entirely preventable through proper medical supervision 1, 2, 3, 4. This is not a theoretical concern—it has caused hospitalizations and deaths 5.